Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142897 | 0.79 | FDPS (0.65) | FDPSSLC6A3ALDH1A1 | |
| SCHEMBL31026681 | 0.76 | FDPS (0.61) | FDPSSLC6A3ALDH1A1 | |
| Phosphoric Acid SCHEMBL6547515 | 0.72 | FDPS (0.56) | FDPSSLC6A3ALDH1A1 | |
| SCHEMBL2035542 | 0.71 | — | — | |
| SCHEMBL9933616 | 0.70 | FDPS (0.54) | FDPSSLC6A3CYP3A4ALDH1A1 | |
| SCHEMBL19468539 | 0.70 | FDPS (0.58) | FDPSALDH1A1 | |
| SCHEMBL104654 | 0.70 | — | — | |
| SCHEMBL9372854 | 0.70 | — | — | |
| SCHEMBL2033995 | 0.69 | FDPS (0.53) | FDPSSLC6A3ALDH1A1 | |
| SCHEMBL6385699 | 0.69 | FDPS (0.53) | FDPSSLC6A3CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | claimed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | claimed |
| US-20130138221-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMPLANT OSSEOINTEGRATION | NOVARTIS AG (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20120027818-A1 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER | GLAUSCH ALEXANDRA (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8052987-B2 | Intermittently administering a bisphosphonate to patient, wherein period between administrations of bisphosphonate is at least 6 months; treatment of osteoporosis | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2011-11-08 | — | — | US | disclosed |
| US-7932241-B2 | Filling plastic container with bisphosphonate solution; heat sterilization | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20090209493-A1 | COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR | BAULCH-BROWN CINDY MAREE | 2009-08-20 | — | — | US | disclosed |
| US-20080254089-A1 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | NOVARTIS PHARMACEUTICALS CORPORATION | 2008-10-16 | — | — | US | disclosed |
| WO-2008116809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A BISPHOSPHONATE AND VITAMIN D | NOVARTIS AG (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1972341-A1 | Pharmaceutical compositions comprising a bisphosphonate and vitamin D | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1418897-A2 | USE OF BISPHOSPHONATES IN THE TREATMENT OF BONE METASTASIS ASSOCIATED WITH PROSTATE CANCER | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004035061-A1 | METHOD OF ADMINISTERING BISPHOSPHONATES | NOVARTIS AG (CH) | 2004-04-29 | — | — | WO | disclosed |
| US-20040063670-A1 | Use of bisphosphonates for pain treatment | FOX ALYSON (GB) | 2004-04-01 | — | — | US | disclosed |
| WO-2004024165-A1 | COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20030181421-A1 | Method of administering bisphosphonates | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-09-25 | — | — | US | disclosed |
| WO-2002087555-A2 | USE OF BISPHOSPHONATES IN THE TREATMENT OF BONE METASTASIS ASSOCIATED WITH PROSTATE CANCER | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | disclosed |
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| US-4939130-A | Substituted alkanediphosphonic acids and pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063670-A1 | Use of bisphosphonates for pain treatment | SOST, OPRL1, BPGM | FDPS 465/4885SLC6A3 424/4885CYP3A4 3800/4885 |
| US-20120027818-A1 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER | PGD, RICTOR, PAICS | FDPS 90/4885SLC6A3 3652/4885CYP3A4 1500/4885 |
| US-20030181421-A1 | Method of administering bisphosphonates | PTH1R, SOST, BPGM | FDPS 620/4885SLC6A3 1574/4885CYP3A4 3119/4885 |
| US-20090209493-A1 | COMBINATION THERAPY COMPRISING A BISPHOSPHONATE AND A HMG-COA REDUCTASE INHIBITOR | HMGCR, BPGM, HMGB2 | FDPS 50/4885SLC6A3 2692/4885CYP3A4 1354/4885 |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | PTEN, PPIP5K2, ACP3 | FDPS 324/4885SLC6A3 246/4885CYP3A4 3060/4885 |
| US-20080254089-A1 | PHARMACEUTICAL PRODUCTS COMPRISING BISPHOSPHONATES | PTH1R, PIK3CA, PPIP5K2 | FDPS 296/4885SLC6A3 1897/4885CYP3A4 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.